Drugs Made in America AcquisDMIIU
13F holders, Q2 2026 (June 30)11holders −3
0new positions
3sold out
$10.16avg. 13F price*
At the end of Q2 2026, 11 institutions reported holding Drugs Made in America Acquis (DMIIU) in their 13F filings, down 3 from Q1 2026. 0 opened new positions and 3 sold out. The largest holders were LMR Partners LLP ($20.3M), Westchester Capital Management, LLC ($5.1M) and BlueCrest Capital Management Ltd ($2.5M).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2851K120
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $7.3M |
All 13F filers, Q1 2026 → Q2 2026: 2 shares bought and 906,894 shares sold, net −906,892 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| LMR Partners LLP | 0.18% | No change | 2,000,000 | $20.3M |
| Westchester Capital Management, LLC | 0.26% | No change | 502,914 | $5.1M |
| BlueCrest Capital Management Ltd | 0.12% | No change | 250,000 | $2.5M |
| Verition Fund Management LLC | 0.02% | No change | 250,000 | $2.5M |
| L1 Global Manager Pty Ltd | 0.85% | No change | 100,000 | $1.0M |
| Readystate Asset Management LP | 0.07% | No change | 100,000 | $1.0M |
| Walleye Capital LLC | 0.01% | No change | 100,000 | $1.0M |
| HRT Financial LP | 0.00% | Reduce -0.3% | 99,725 | $1.0M |
| Rangeley Capital, LLC | 0.33% | Reduce -41.5% | 32,551 | $331K |
| Clear Street Group Inc. | 0.00% | Reduce -95.2% | 8,084 | $82K |
| UBS Group AG | 0.00% | Add +0.1% | 1,765 | $18K |
"% of holder's portfolio" is DMIIU's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.